There has been a plethora of news surrounding the pharmaceutical giant Bristol-Myers Squibb (BMY). Investors are expected to monitor several key elements ahead of the opening bell on Monday, including the dividend date, earnings, and 2026 catalysts. Many investment firms have increased their stake in BMY. Even after a recent price rebound, the stock continues to appear undervalued. Meanwhile, impressive gains are recorded, yet challenging tests are anticipated. BMY was upgraded from neutral to buy by Bank of America. BMY's shares moved upward after a slew of positive institutional filings. The U.S. FDA approved Bristol Myers Squibb’s drug, Breyanzi, as the only CAR T therapy for adults with refractory marginal zone lymphoma. Analyst estimations depict a bright future despite a $6.6 billion one-off loss challenging the quality of recent earnings. Analysts also see it as a top value stock for the long-term, with a strong growth pipeline supporting a high-yield dividend. The stock continues attracting investors, showing resilence in market declines. Other important notes include a Buy rating at Guggenheim amid competitive markets and an upcoming focus on oncology pipeline momentum following a significant dividend hike.
Bristol-Myers Squibb BMY News Analytics from Thu, 31 Jul 2025 07:00:00 GMT to Sat, 27 Dec 2025 22:49:12 GMT - Rating 6 - Innovation 8 - Information 8 - Rumor -2
